AnaptysBio, Inc. (ANAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
AnaptysBio, Inc. (ANAB)
Last anaptysbio, inc. earnings: 3/2 08:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.anaptysbio.com/investor-relations
Company Research
Source: Seeking Alpha
Company Participants Daniel Faga - President, CEO & Director Conference Call Participants Etzer Darout - Barclays Bank PLC, Research Division Presentation Etzer Darout Barclays Bank PLC, Research Division Hello again, everyone. I'm Etzer Darout, senior biotech analyst at Barclays. My pleasure to have AnaptysBio CEO, Dan Faga, with us this morning. And maybe just to kick us off, Dan, if you could just give us an overview of AnaptysBio for those less familiar with the story. Daniel Faga President, CEO & Director Perfect. We're in exciting times right now. We're approximately a month or 2 out from creating a second company called First Tracks Bio, which will be the biopharma operations from Anaptys that we're spinning off. Anaptys has been around for over 20 years, developing antibodies. We have 2 successful programs so far out of our platform, one Jemperli dostarlimab, which is being sold by GSK, it's an oncology drug PD-1 antagonist. And the second has a PDUFA da
Show less
Read more
Impact Snapshot
Event Time:
ANAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANAB alerts
High impacting AnaptysBio, Inc. news events
Weekly update
A roundup of the hottest topics
ANAB
News
- AnaptysBio (ANAB) had its price target raised by Wedbush from $60.00 to $75.00. They now have an "outperform" rating on the stock.MarketBeat
- AnaptysBio Plans First Tracks Spin-Off as Jemperli Royalties Surge, Buybacks Possible [Yahoo! Finance]Yahoo! Finance
- AnaptysBio (ANAB) was given a new $50.00 price target by Truist Financial Corporation.MarketBeat
- Assessing AnaptysBio (ANAB) Valuation After Profitability Turnaround And Strong Jemperli Royalty Progress [Yahoo! Finance]Yahoo! Finance
- AnaptysBio (ANAB) had its price target raised by Stifel Nicolaus from $56.00 to $85.00. They now have a "buy" rating on the stock.MarketBeat
ANAB
Earnings
- 3/3/26 - Beat
ANAB
Sec Filings
- 3/3/26 - Form 10-K
- 3/3/26 - Form 8-K
- 2/13/26 - Form 4
- ANAB's page on the SEC website